

BRD4 domain 2

PDB:2OUO

Revision

Revision Type:created

Revised by:created

Revision Date:created

Entry Clone Accession:NP_055114.1

Entry Clone Source:FivePrime

SGC Clone Accession:

Tag:Tag sequence: mhhhhhssgvdlgtenlyfq*s(m) ; TEV-cleavable (*) N-terminal his6 tag

Host:BL21 (DE3)

Construct

Prelude:

Sequence:

mhhhhhssgvdlgtenlyfqsmKDVPDS QQHPAPEKSSKVSEQLKCCSGILKEMFAK KHAAYAWPFYKPVDVEALGLHDYCDII
KH PMDMSTIKSKLEAREYRDAQEFGADVRLM FSNCYKYNPPDHEVVAMARKLQDVFEMRF AKMPDE

Vector:pNIC28-Bsa4

Growth

Medium:LB

Antibiotics:

Procedure:Grow starter cultures from freshly transformed colonies in 10 ml LB, 50 mg/ml kanamycin. This started culture was diluted 1:1000 in fresh media and was grown at 37°C to a OD600 of 0.4 and then transferred to 18 degC. Expression was induced at an OD600 of 0.6 - 0.7 using 1 mM IPTG (final concentration). Cells were harvested after 4h by centrifugation (15min, 6500rpm on a JLA 8.100 rotor), transferred to 50-ml tubes, and frozen at -20 degC.

Purification

Procedure

Column 1 : DE52/Ni-NTA

A DE52 column (10gr suspended in 100ml of 2.5M NaCl) was equilibrated with 100ml of Loading Buffer. A 5ml NiNTA column was equilibrated with 20ml of Loading Buffer. The lysed sample was applied to the DE-52 column and washed through with 50 ml loading buffer. The flow through was applied to the 5 ml Ni-NTA column which was washed with 2x10ml of wash buffer and eluted with elution buffer in 5 ml aliquots. (Step elution using 50, 100, 150, 200 and 250 mM imidazole in the Elution Buffer)

Enzymatic treatment : Treated the IMAC elution(s) with TEV protease overnight.

Column 2 : SEC (AKTA-prime)

Fractions containing BRD4A collected from IMAC and treated with TEV protease overnight (identified by SDS PAGE) were concentrated to about 1.5ml and directly applied to a S75 16/60 column equilibrated in 10 mM Hepes pH 7.5, 100 mM NaCl. The flow rate was 1ml/min and the pure protein eluted at 76-88min.

Concentration : The combined samples from the SEC column (identified by SDS PAGE) were concentrated using centricons with 10 kDa cut off.

Extraction

Procedure

The cell pellets (5 gr wet wt) were re-suspended in 50 ml extraction buffer containing a Protease Inhibitor Cocktail tablet (Roche), and lysed in a high pressure cell disrupter. The supernatant was centrifuged for 45 minutes at 53k g in a JA 25.5 rotor.

Concentration:

Ligand

MassSpec: LC-ESI-MS/MS confirmed the correct mass of 15036 expected for this construct after TEV treatment.

Crystallization: Crystals were grown at 4 degC in 150nl sitting drops mixing 75 nl of BRD4A (19 mg/ml in 10mM Hepes pH 7.5, 100mM NaCl, 10mM DTT) with 75 nl of a solution containing 0.1M MIB pH 7.0 and 30.0% PEG 1K. Cryo protection was achieved by adding ethylene glycole to the crystallization mix (20% final w/v).

NMR Spectroscopy:

Data Collection: Resolution: 1.89Å; X-ray source: Rotating anode, Rigaku FR-E superbright.

Data Processing: